Numerai’s Indivior Pharmaceuticals INDV Stock Holding History

Numerai’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-33,149	Closed	-$799K	–	678
2025 Q3	$799K	Buy	+33,149	New	+$694K	0.11%	243

Other funds holding INDV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Numerai's INDV Position: Q4 2025 in Review

Numerai sold out of Indivior Pharmaceuticals (INDV) in Q4 2025, closing a stake of 33,149 shares — an estimated $799K sold.

Numerai first reported a position in INDV in Q3 2025 and held it in 1 quarter. The position peaked at $799K in Q3 2025. 259 funds tracked by Wall St. Rank hold INDV as of Q4 2025.

Numerai reported no remaining Indivior Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Numerai sold 33,149 Indivior Pharmaceuticals shares in Q4 2025, an estimated $799K.
Numerai first reported a position in Indivior Pharmaceuticals in Q3 2025 and held it in 1 quarter.
Numerai's Indivior Pharmaceuticals position peaked at $799K in Q3 2025.
259 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q4 2025.

Based on Numerai's 13F filing for Q4 2025, filed 17 Feb 2026.